t cell depletion Search Results


human tcrɑ β depletion kit  (Miltenyi Biotec)
94
Miltenyi Biotec human tcrɑ β depletion kit
Human Tcrɑ β Depletion Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cell+depletion/TCR%CE%B1%2F%CE%B2+T+Cell+Depletion+Kit%2C+human/pm39962112-258-23-27
Average 94 stars, based on 1 article reviews
human tcrɑ β depletion kit - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
autologous t-cell depleted pbmcs  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc autologous t-cell depleted pbmcs
T-cell characterization. A–C, immunoSEQ Analyzer differential abundance analysis displayed in pairwise scatter plots are shown for subjects 1, 2, and 3, respectively. The frequency of productive TCRβ rearrangements (clones) from the peripheral blood before and after NeoVax is compared. No data are available for subject 4 because they did not receive NeoVax. D–M, Bar graphs displaying IFNγ spots from IFNγ ELISPOT assays. Experiments were performed with duplicate or triplicate wells, and biological replicates were performed at least twice. *, P < 0.05 (Student t test) between pre- and post-NeoVax responses. There were 84, 77, and 35 days between pre- and post-NeoVax peripheral blood collections for subjects 1, 2, and 3, respectively. D, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 post-NeoVax. E, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 post-NeoVax. F, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 pre-NeoVax. G, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 pre-NeoVax. H–M, In vitro expanded <t>PBMCs</t> from pre- and postvaccination time points stimulated with IL2 and corresponding SLPs (green bars), minimal epitope peptide pools (dark orange bars), or DMSO control (purple bars) for 12 days prior to restimulation and analysis for subjects 1, 2, and 3.
Autologous T Cell Depleted Pbmcs, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cell+depletion/autologous+t+cell+depleted+pbmcs/pmc11215407-107-11-15
Average 90 stars, based on 1 article reviews
autologous t-cell depleted pbmcs - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
stemsep human cd3+ t cell depletion  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc stemsep human cd3+ t cell depletion
T-cell characterization. A–C, immunoSEQ Analyzer differential abundance analysis displayed in pairwise scatter plots are shown for subjects 1, 2, and 3, respectively. The frequency of productive TCRβ rearrangements (clones) from the peripheral blood before and after NeoVax is compared. No data are available for subject 4 because they did not receive NeoVax. D–M, Bar graphs displaying IFNγ spots from IFNγ ELISPOT assays. Experiments were performed with duplicate or triplicate wells, and biological replicates were performed at least twice. *, P < 0.05 (Student t test) between pre- and post-NeoVax responses. There were 84, 77, and 35 days between pre- and post-NeoVax peripheral blood collections for subjects 1, 2, and 3, respectively. D, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 post-NeoVax. E, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 post-NeoVax. F, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 pre-NeoVax. G, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 pre-NeoVax. H–M, In vitro expanded <t>PBMCs</t> from pre- and postvaccination time points stimulated with IL2 and corresponding SLPs (green bars), minimal epitope peptide pools (dark orange bars), or DMSO control (purple bars) for 12 days prior to restimulation and analysis for subjects 1, 2, and 3.
Stemsep Human Cd3+ T Cell Depletion, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cell+depletion/stemsep+human+cd3++t+cell+depletion/pm25229165-66-0-6
Average 90 stars, based on 1 article reviews
stemsep human cd3+ t cell depletion - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
t-cell–depleted bm  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc t-cell–depleted bm
T-cell characterization. A–C, immunoSEQ Analyzer differential abundance analysis displayed in pairwise scatter plots are shown for subjects 1, 2, and 3, respectively. The frequency of productive TCRβ rearrangements (clones) from the peripheral blood before and after NeoVax is compared. No data are available for subject 4 because they did not receive NeoVax. D–M, Bar graphs displaying IFNγ spots from IFNγ ELISPOT assays. Experiments were performed with duplicate or triplicate wells, and biological replicates were performed at least twice. *, P < 0.05 (Student t test) between pre- and post-NeoVax responses. There were 84, 77, and 35 days between pre- and post-NeoVax peripheral blood collections for subjects 1, 2, and 3, respectively. D, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 post-NeoVax. E, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 post-NeoVax. F, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 pre-NeoVax. G, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 pre-NeoVax. H–M, In vitro expanded <t>PBMCs</t> from pre- and postvaccination time points stimulated with IL2 and corresponding SLPs (green bars), minimal epitope peptide pools (dark orange bars), or DMSO control (purple bars) for 12 days prior to restimulation and analysis for subjects 1, 2, and 3.
T Cell–Depleted Bm, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cell+depletion/t+cell+depleted+bm/pmc11334836-97-20-24
Average 90 stars, based on 1 article reviews
t-cell–depleted bm - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
ceprate t-cell depletion system  (CellPro Inc)
90
CellPro Inc ceprate t-cell depletion system
T-cell characterization. A–C, immunoSEQ Analyzer differential abundance analysis displayed in pairwise scatter plots are shown for subjects 1, 2, and 3, respectively. The frequency of productive TCRβ rearrangements (clones) from the peripheral blood before and after NeoVax is compared. No data are available for subject 4 because they did not receive NeoVax. D–M, Bar graphs displaying IFNγ spots from IFNγ ELISPOT assays. Experiments were performed with duplicate or triplicate wells, and biological replicates were performed at least twice. *, P < 0.05 (Student t test) between pre- and post-NeoVax responses. There were 84, 77, and 35 days between pre- and post-NeoVax peripheral blood collections for subjects 1, 2, and 3, respectively. D, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 post-NeoVax. E, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 post-NeoVax. F, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 pre-NeoVax. G, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 pre-NeoVax. H–M, In vitro expanded <t>PBMCs</t> from pre- and postvaccination time points stimulated with IL2 and corresponding SLPs (green bars), minimal epitope peptide pools (dark orange bars), or DMSO control (purple bars) for 12 days prior to restimulation and analysis for subjects 1, 2, and 3.
Ceprate T Cell Depletion System, supplied by CellPro Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cell+depletion/ceprate+t+cell+depletion+system/pm16041312-43-17-20
Average 90 stars, based on 1 article reviews
ceprate t-cell depletion system - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
t cell-depleted splenocytes  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc t cell-depleted splenocytes
T-cell characterization. A–C, immunoSEQ Analyzer differential abundance analysis displayed in pairwise scatter plots are shown for subjects 1, 2, and 3, respectively. The frequency of productive TCRβ rearrangements (clones) from the peripheral blood before and after NeoVax is compared. No data are available for subject 4 because they did not receive NeoVax. D–M, Bar graphs displaying IFNγ spots from IFNγ ELISPOT assays. Experiments were performed with duplicate or triplicate wells, and biological replicates were performed at least twice. *, P < 0.05 (Student t test) between pre- and post-NeoVax responses. There were 84, 77, and 35 days between pre- and post-NeoVax peripheral blood collections for subjects 1, 2, and 3, respectively. D, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 post-NeoVax. E, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 post-NeoVax. F, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 pre-NeoVax. G, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 pre-NeoVax. H–M, In vitro expanded <t>PBMCs</t> from pre- and postvaccination time points stimulated with IL2 and corresponding SLPs (green bars), minimal epitope peptide pools (dark orange bars), or DMSO control (purple bars) for 12 days prior to restimulation and analysis for subjects 1, 2, and 3.
T Cell Depleted Splenocytes, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cell+depletion/t+cell+depleted+splenocytes/pmc04779695-63-60-68
Average 90 stars, based on 1 article reviews
t cell-depleted splenocytes - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
cd8+ t cell depletion kit  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc cd8+ t cell depletion kit
T-cell characterization. A–C, immunoSEQ Analyzer differential abundance analysis displayed in pairwise scatter plots are shown for subjects 1, 2, and 3, respectively. The frequency of productive TCRβ rearrangements (clones) from the peripheral blood before and after NeoVax is compared. No data are available for subject 4 because they did not receive NeoVax. D–M, Bar graphs displaying IFNγ spots from IFNγ ELISPOT assays. Experiments were performed with duplicate or triplicate wells, and biological replicates were performed at least twice. *, P < 0.05 (Student t test) between pre- and post-NeoVax responses. There were 84, 77, and 35 days between pre- and post-NeoVax peripheral blood collections for subjects 1, 2, and 3, respectively. D, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 post-NeoVax. E, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 post-NeoVax. F, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 pre-NeoVax. G, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 pre-NeoVax. H–M, In vitro expanded <t>PBMCs</t> from pre- and postvaccination time points stimulated with IL2 and corresponding SLPs (green bars), minimal epitope peptide pools (dark orange bars), or DMSO control (purple bars) for 12 days prior to restimulation and analysis for subjects 1, 2, and 3.
Cd8+ T Cell Depletion Kit, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cell+depletion/cd8++t+cell+depletion+kit/pmc04280322-126-12-17
Average 90 stars, based on 1 article reviews
cd8+ t cell depletion kit - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
haploidentical hct with tcr+ t cell/cd19+ depletion  (Johns Hopkins HealthCare)
90
Johns Hopkins HealthCare haploidentical hct with tcr+ t cell/cd19+ depletion
T-cell characterization. A–C, immunoSEQ Analyzer differential abundance analysis displayed in pairwise scatter plots are shown for subjects 1, 2, and 3, respectively. The frequency of productive TCRβ rearrangements (clones) from the peripheral blood before and after NeoVax is compared. No data are available for subject 4 because they did not receive NeoVax. D–M, Bar graphs displaying IFNγ spots from IFNγ ELISPOT assays. Experiments were performed with duplicate or triplicate wells, and biological replicates were performed at least twice. *, P < 0.05 (Student t test) between pre- and post-NeoVax responses. There were 84, 77, and 35 days between pre- and post-NeoVax peripheral blood collections for subjects 1, 2, and 3, respectively. D, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 post-NeoVax. E, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 post-NeoVax. F, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 pre-NeoVax. G, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 pre-NeoVax. H–M, In vitro expanded <t>PBMCs</t> from pre- and postvaccination time points stimulated with IL2 and corresponding SLPs (green bars), minimal epitope peptide pools (dark orange bars), or DMSO control (purple bars) for 12 days prior to restimulation and analysis for subjects 1, 2, and 3.
Haploidentical Hct With Tcr+ T Cell/Cd19+ Depletion, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cell+depletion/haploidentical+hct+with+tcr++t+cell+cd19++depletion/10__1016_slash_s2666___6367_ascii40_23_ascii41_00464___5-61-28-36
Average 90 stars, based on 1 article reviews
haploidentical hct with tcr+ t cell/cd19+ depletion - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
t cell depletion  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc t cell depletion
T-cell characterization. A–C, immunoSEQ Analyzer differential abundance analysis displayed in pairwise scatter plots are shown for subjects 1, 2, and 3, respectively. The frequency of productive TCRβ rearrangements (clones) from the peripheral blood before and after NeoVax is compared. No data are available for subject 4 because they did not receive NeoVax. D–M, Bar graphs displaying IFNγ spots from IFNγ ELISPOT assays. Experiments were performed with duplicate or triplicate wells, and biological replicates were performed at least twice. *, P < 0.05 (Student t test) between pre- and post-NeoVax responses. There were 84, 77, and 35 days between pre- and post-NeoVax peripheral blood collections for subjects 1, 2, and 3, respectively. D, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 post-NeoVax. E, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 post-NeoVax. F, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 pre-NeoVax. G, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 pre-NeoVax. H–M, In vitro expanded <t>PBMCs</t> from pre- and postvaccination time points stimulated with IL2 and corresponding SLPs (green bars), minimal epitope peptide pools (dark orange bars), or DMSO control (purple bars) for 12 days prior to restimulation and analysis for subjects 1, 2, and 3.
T Cell Depletion, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cell+depletion/t+cell+depletion/pmc08147650-83-18-20
Average 90 stars, based on 1 article reviews
t cell depletion - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
cepratetcd t cell depletion system  (CellPro Inc)
90
CellPro Inc cepratetcd t cell depletion system
T-cell characterization. A–C, immunoSEQ Analyzer differential abundance analysis displayed in pairwise scatter plots are shown for subjects 1, 2, and 3, respectively. The frequency of productive TCRβ rearrangements (clones) from the peripheral blood before and after NeoVax is compared. No data are available for subject 4 because they did not receive NeoVax. D–M, Bar graphs displaying IFNγ spots from IFNγ ELISPOT assays. Experiments were performed with duplicate or triplicate wells, and biological replicates were performed at least twice. *, P < 0.05 (Student t test) between pre- and post-NeoVax responses. There were 84, 77, and 35 days between pre- and post-NeoVax peripheral blood collections for subjects 1, 2, and 3, respectively. D, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 post-NeoVax. E, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 post-NeoVax. F, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 pre-NeoVax. G, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 pre-NeoVax. H–M, In vitro expanded <t>PBMCs</t> from pre- and postvaccination time points stimulated with IL2 and corresponding SLPs (green bars), minimal epitope peptide pools (dark orange bars), or DMSO control (purple bars) for 12 days prior to restimulation and analysis for subjects 1, 2, and 3.
Cepratetcd T Cell Depletion System, supplied by CellPro Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cell+depletion/cepratetcd+t+cell+depletion+system/pm10691874-52-15-20
Average 90 stars, based on 1 article reviews
cepratetcd t cell depletion system - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
t-cell deplete ahst  (Schmid GmbH)
90
Schmid GmbH t-cell deplete ahst
T-cell characterization. A–C, immunoSEQ Analyzer differential abundance analysis displayed in pairwise scatter plots are shown for subjects 1, 2, and 3, respectively. The frequency of productive TCRβ rearrangements (clones) from the peripheral blood before and after NeoVax is compared. No data are available for subject 4 because they did not receive NeoVax. D–M, Bar graphs displaying IFNγ spots from IFNγ ELISPOT assays. Experiments were performed with duplicate or triplicate wells, and biological replicates were performed at least twice. *, P < 0.05 (Student t test) between pre- and post-NeoVax responses. There were 84, 77, and 35 days between pre- and post-NeoVax peripheral blood collections for subjects 1, 2, and 3, respectively. D, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 post-NeoVax. E, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 post-NeoVax. F, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 pre-NeoVax. G, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 pre-NeoVax. H–M, In vitro expanded <t>PBMCs</t> from pre- and postvaccination time points stimulated with IL2 and corresponding SLPs (green bars), minimal epitope peptide pools (dark orange bars), or DMSO control (purple bars) for 12 days prior to restimulation and analysis for subjects 1, 2, and 3.
T Cell Deplete Ahst, supplied by Schmid GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cell+depletion/t+cell+deplete+ahst/pm29193005-5-3-14
Average 90 stars, based on 1 article reviews
t-cell deplete ahst - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
easysep mouse memory t cell depletion cocktail  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc easysep mouse memory t cell depletion cocktail
T-cell characterization. A–C, immunoSEQ Analyzer differential abundance analysis displayed in pairwise scatter plots are shown for subjects 1, 2, and 3, respectively. The frequency of productive TCRβ rearrangements (clones) from the peripheral blood before and after NeoVax is compared. No data are available for subject 4 because they did not receive NeoVax. D–M, Bar graphs displaying IFNγ spots from IFNγ ELISPOT assays. Experiments were performed with duplicate or triplicate wells, and biological replicates were performed at least twice. *, P < 0.05 (Student t test) between pre- and post-NeoVax responses. There were 84, 77, and 35 days between pre- and post-NeoVax peripheral blood collections for subjects 1, 2, and 3, respectively. D, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 post-NeoVax. E, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 post-NeoVax. F, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 pre-NeoVax. G, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 pre-NeoVax. H–M, In vitro expanded <t>PBMCs</t> from pre- and postvaccination time points stimulated with IL2 and corresponding SLPs (green bars), minimal epitope peptide pools (dark orange bars), or DMSO control (purple bars) for 12 days prior to restimulation and analysis for subjects 1, 2, and 3.
Easysep Mouse Memory T Cell Depletion Cocktail, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/t+cell+depletion/easysep+mouse+memory+t+cell+depletion+cocktail/pmc07478024-58-24-31
Average 90 stars, based on 1 article reviews
easysep mouse memory t cell depletion cocktail - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


T-cell characterization. A–C, immunoSEQ Analyzer differential abundance analysis displayed in pairwise scatter plots are shown for subjects 1, 2, and 3, respectively. The frequency of productive TCRβ rearrangements (clones) from the peripheral blood before and after NeoVax is compared. No data are available for subject 4 because they did not receive NeoVax. D–M, Bar graphs displaying IFNγ spots from IFNγ ELISPOT assays. Experiments were performed with duplicate or triplicate wells, and biological replicates were performed at least twice. *, P < 0.05 (Student t test) between pre- and post-NeoVax responses. There were 84, 77, and 35 days between pre- and post-NeoVax peripheral blood collections for subjects 1, 2, and 3, respectively. D, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 post-NeoVax. E, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 post-NeoVax. F, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 pre-NeoVax. G, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 pre-NeoVax. H–M, In vitro expanded PBMCs from pre- and postvaccination time points stimulated with IL2 and corresponding SLPs (green bars), minimal epitope peptide pools (dark orange bars), or DMSO control (purple bars) for 12 days prior to restimulation and analysis for subjects 1, 2, and 3.

Journal: Clinical Cancer Research

Article Title: Integrating Multisector Molecular Characterization into Personalized Peptide Vaccine Design for Patients with Newly Diagnosed Glioblastoma

doi: 10.1158/1078-0432.CCR-23-3077

Figure Lengend Snippet: T-cell characterization. A–C, immunoSEQ Analyzer differential abundance analysis displayed in pairwise scatter plots are shown for subjects 1, 2, and 3, respectively. The frequency of productive TCRβ rearrangements (clones) from the peripheral blood before and after NeoVax is compared. No data are available for subject 4 because they did not receive NeoVax. D–M, Bar graphs displaying IFNγ spots from IFNγ ELISPOT assays. Experiments were performed with duplicate or triplicate wells, and biological replicates were performed at least twice. *, P < 0.05 (Student t test) between pre- and post-NeoVax responses. There were 84, 77, and 35 days between pre- and post-NeoVax peripheral blood collections for subjects 1, 2, and 3, respectively. D, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 post-NeoVax. E, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 post-NeoVax. F, Direct ex vivo stimulation on select CD8 + T cells with minimal epitope peptide pools (m) or DMSO control for subject 1 pre-NeoVax. G, Direct ex vivo stimulation on select CD4 + T cells with SLPs or DMSO control for subject 1 pre-NeoVax. H–M, In vitro expanded PBMCs from pre- and postvaccination time points stimulated with IL2 and corresponding SLPs (green bars), minimal epitope peptide pools (dark orange bars), or DMSO control (purple bars) for 12 days prior to restimulation and analysis for subjects 1, 2, and 3.

Article Snippet: On day 13, cells were restimulated with 1 × 10 5 autologous T-cell depleted PBMCs (STEMCELL Technologies) and respective neoantigen minimal epitope peptide pools, the full-length peptide, or DMSO in a human IFNγ ELISPOT plate (ImmunoSpot).

Techniques: Clone Assay, Enzyme-linked Immunospot, Ex Vivo, Control, In Vitro